At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCDA BioCardia
Trading 03-27 10:31:31 EDT
1.16
-0.02
-1.69%
High1.23
Low1.16
Vol5.85K
Open1.20
D1 Closing1.18
Amplitude5.92%
Mkt Cap12.69M
Tradable Cap4.70M
Total Shares10.94M
T/O7.01K
T/O Rate0.14%
Tradable Shares4.05M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
BioCardia President and CEO Peter Altman acquires common shares; purchases total $1,110
BioCardia Announces Late Breaking Echocardiography Results From the Cardiamp HF Trial to Be Presented at Technology and Heart Failure Therapeutics (Tht)
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.